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existing  condition  using  chemotherapy,  radiation  therapy, 
immunosuppressive  therapy,  or  a  combination  of  these  modalities  may  lead  to  the  devastating 
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direct consequence of mutational events induced by the primary treatment.  The outcomes for these 
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Case Presentation: A 46-year-old woman was diagnosed with localized breast cancer.  She underwent 
primary excision followed by adjuvant chemotherapy with doxorubicin and cyclophosphamide followed 
by paclitaxel; filgrastim was given to maintain a dose-dense schedule.  Finally, she received radiation 
therapy to the left chest wall. No recurrence of breast cancer has been detected on routine follow up and 
imaging. However, 3 years  later, she was noted to have pancytopenia.  A bone  marrow examination 
revealed a markedly hypercellular marrow with 90% malignant promyelocytes and blasts. The karyotype 
was 46XX,t(15;17) in all 30 metaphase cells.  Her cardiac left ventricular ejection fraction has declined 
to 40%. 
Is this therapy-related acute promyelocytic leukemia (t-APL)?  Will it respond differently than de novo 
APL?    Can  it  be  treated  successfully  without  exposure  to  additional  anthracyclines  or  the  use  of 
hematopoietic  stem  cell  transplantation  (HCT)?    Do  “cytogenetically  favorable”  subsets  of  therapy-
related myeloid leukemia (t-AML) have a different outcome than more typical cases of t-AML with 
complex cytogenetic abnormalities? 
 
The  Syndrome  of  Therapy-Related  Myeloid 
Neoplasm:  Treatment  for  a  pre-existing  condition 
using  chemotherapy,  radiation  therapy, 
immunosuppressive therapy, or a combination of these 
modalities may lead to the devastating complication of 
therapy-related  myelodysplastic  syndrome  or  acute 
myeloid leukemia (t-MDS/t-AML), collectively known 
as  therapy-related  myeloid  neoplasm  (t-MN).
1  This 
disorder arises as a direct consequence of mutational 
events induced by the primary treatment. The outcomes 
for these patients have been historically poor compared 
to  people  who  develop  AML  de  novo.    Currently 
comprising  10-20%  of  all  cases  of  AML,  t-MN  is 
relatively resistant to conventional leukemia therapies, 
and is associated with short survival times.
1-3 Median 
life expectancy from diagnosis is about 8-10 months in 
most  series.
2  Although  the  spectrum  of  cytogenetic 
abnormalities in t-AML is similar to AML de novo, the 
frequency  of  unfavorable  cytogenetics,  such  as  a 
complex karyotype or deletion or loss of chromosome 
5 and/or 7, is considerably higher in t-MN.
2 
Two  distinct  groups  of  patients  with  t-MN  have 
been described.
1,2,4,5 The more common subtype, seen 
in  about  75%  of  patients,  typically  occurs  5-7  years 
after first exposure to alkylating agents or radiation, is 
often preceded by a myelodysplastic syndrome (MDS), 
and  is  frequently  accompanied  by  clonal  cytogenetic 
abnormalities  such  as  the  loss  of  all  or  part  of 
chromosomes  5  or  7.  Mutations  of  the  P53  tumor 
suppressor gene are also common. The risk is related to 
total  cumulative  exposure  over  time  to  alkylating 
agents. In contrast, among individuals who develop t-
AML after treatment with topoisomerase II inhibitors, 
the  latency  period  to  the  development  of  t-AML  is 
often only 1-3 years, antecedent MDS is rare, and gene 
rearrangements  involving  MLL  at  11q23  or 
RUNX1/AML1  at  21q22  are  common.  Risk  is  less 
clearly  related  to  total  cumulative  dose  but  is 
associated with chemotherapy dose and schedule.  
 
The  Importance  of  Cytogenetic  Abnormalities  in 
Predicting Patient Outcomes: Within a series of 306 
patients  with  t-MN  studied  at  the  University  of 
Chicago, the median survival rate was approximately 7 
to 9 months, and varied with karyotype.
2 The longest 
median overall survival rates were seen in patients with 
normal  karyotypes  or  recurring  balanced 
rearrangements  (approximately  11  months  each). 
However, the incidence of unfavorable karyotypes was 
greater  than  70%.  The  shortest  median  survival  was 
seen  in  patients  with  abnormalities  of  both 
chromosomes 5 and 7 (approximately 5 months). Only  
24  patients  (8%)  were  alive  3  years  after  diagnosis.  
Patients  with  t-MN  who  responded  to  remission 
induction  therapy  but  subsequently  died  from  their 
primary  malignancy  were  included  in  the  survival 
analysis.  The  short  survivals  reported  in  this  early 
series  compared  with  more  recent  series  described 
below  reflects  a  higher  percentage  of  patients  who 
received  only  supportive  care  rather  than  undergo 
remission induction chemotherapy at that time. 
Survival for patients receiving intensive remission 
induction  chemotherapy  varies  according  to 
cytogenetic risk group.  Better outcomes are observed 
in t-MN patients with more favorable-risk karyotypes.  
A large comparative analysis reported by the German 
AML Cooperative Group included 93 patients with t-
AML  and  1091  patients  with  de  novo  AML  treated 
with  standard  AML  induction  therapy.
6  Overall,  the 
median survival was 10 months for patients with t- 
AML compared to 15 months for patients with de 
novo  AML  (P=0.0007).  Favorable,  intermediate,  and 
unfavorable karyotypes were observed in 26%, 28%, 
and  46%  of  t-AML  patients,  and  in  22%,  57%,  and 
20% of de novo AML patients. The high frequency of
Table 1. Survival according to cytogenetic risk group for patients with t-AML or de novo AML treated by the German AML Cooperative Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
Group (AMLCG)
7 
Karyotype  No. of patients (%)  Median survival (months) 
  t-AML (n=121)  de novo AML (n=1511)  t -AML  de novo AML  p 
Favorable  29 (24)  306 (20)  27  >60  0.02 
Intermediate  34 (28)  903 (60)  12  16  0.19 
Unfavorable  58 (48)  302 (20)  6  7  0.006 
 
adverse cytogenetics may explain to a large extent the 
unfavorable  outcomes  of  patients  with  t-AML. 
Although favorable and unfavorable cytogenetics had 
prognostic value in both patient groups, the survival of 
patients with t-AML was generally shorter than that of 
those with de novo AML within the same cytogenetic 
risk group. When updated to include 121 patients with 
t-AML, the median overall survival times for patients 
with  t-AML  with  favorable,  intermediate,  and 
unfavorable cytogenetics were 27, 13, and 6 months, 
respectively  (Table  1).
7  For  those  with  a  favorable 
karyotype,  the  median  survival  was  not  yet  reached 
after  5  years  for  the  306  de  novo  AML  patients 
compared  to  27  months  for  the  29  t-AML  patients 
(P=0.02).  Some of these t-AML patients appeared to 
be cured. Within the large intermediate risk cytogenetic 
group,  no  significant  difference  in  survival  was 
observed  between  the  t-AML  and  de  novo  AML 
patients.  An unfavorable karyotype predicated a very 
short survival in both groups of AML patients. 
Armand et al analyzed the outcomes of 80 patients 
with  therapy-related  leukemia  treated  at  the  Dana 
Farber  Cancer  Institute  in  Boston.
8  They  found  that 
cytogenetic abnormalities were the strongest predictors 
for  overall  survival.    When  adjusted  for  cytogenetic 
changes,  the  patients  with  t-AML  did  as  well  as 
patients with de novo AML, further emphasizing the 
importance of cytogenetic abnormalities in predicting 
severity of disease and outcomes. 
Kayser et al   recently   reported  on  200  patients  
with t-AML and compared their clinical and biological 
characteristics  and  outcomes  with  those  of  2653 
patients with de novo AML treated on 6 prospective 
multi-center trials by the German-Austrian AML Study 
Group.
3 Seventy-five percent of the t-AML cases had 
an  abnormal  karyotype  compared  to  51%  of  the  de 
novo cases, and 15% of the t-AML cases had either a 
t(15;17)  [2%],  t(8;21)  [5%],  or  inv(16)  or  t(16;16) 
[8%].  The t-AML patients were older (median, 58 vs 
53 years; p<0.0001) and more often female (68% vs 
47%;  p<0.0001).  The  median  latency  was  4.0  years 
(range,  0.3  to  44  years).   The response to  remission 
induction therapy was 63% CR for t-AML and 67% for 
de novo AML (p=0.21).  However, the outcome for t-
AML patients was significantly inferior. Relapse-free 
survival at 4 years was 25% for t-AML and 40% for de 
novo  AML  (p<0.0001).  In  multivariable  models 
adjusted  for  white  blood cell  counts,  among  patients 
with an inv(16) or t(16;16), t-AML was a significant 
adverse prognostic factor for overall survival (hazard 
ratio 2.35; p=0.04). 
 
Factors That Influence Outcome in t-MN: Therapy-
related myeloid leukemia is generally a fatal disease.  
The life-threatening complications of this disorder are 
the result of persistent and profound cytopenias due to 
the failure of normal hematopoiesis regardless of the 
fraction  of  myeloblasts  accumulating  in  the  bone 
marrow or blood.  There has been general agreement 
that patients with t-AML  have shorter survivals than 
patients with de novo AML.  Supportive care is still 
considered by many to be the standard management. 
The  survival  of  patients  with  t-MN  is  often  poor 
despite  prompt  diagnosis  and  treatment.    However, 
there is a paucity of prospective treatment data since 
these patients are most often excluded from frontline 
clinical  trials.    There  are  no  randomized  studies 
comparing  standard  AML  therapy  to  other  forms  of 
treatment.  A  number  of  potential  factors  explain  the 
poor  outcome  of  patients  with  t-MN.  Poor 
hematopoietic reserves can make the administration of 
standard AML therapy difficult. Because t-MN evolves 
in the milieu of chemotherapy, the malignant cells may 
be  more  drug-resistant  than  in  de  novo  disease.  
Persistence  of  the  primary  malignant  disease, 
particularly  metastatic  cancer  or  lymphoma,  causes 
morbidity  and  mortality  independent  of  the  bone 
marrow  failure  caused  by  leukemia.  Many  patients 
have poor tolerance for the acute toxicity of treatment.  
Injury to organs and their vascular supply from prior 
treatment may compromise the ability of these patients 
to receive intensive chemotherapy or successful HCT. 
There may be depletion of normal hematopoietic stem  
cells  as  a  consequence  of  previous  therapy,  so  that 
these  patients  suffer  prolonged  cytopenias  after 
induction chemotherapy. The bone marrow stroma may 
have been damaged, especially by therapeutic radiation 
to fields that include the pelvis or lumbosacral spine, so 
that  it  will  not  support  regeneration  of  normal 
hematopoiesis.  Patients  with  t-AML  are  often 
chronically immunosuppressed from prior disease or  
on-going  therapy  or  may  have  dysfunctional  and 
dysplastic  phagocytes,  and  thus  are  often  colonized 
with  pathogenic  or  antibiotic-resistant  bacteria  and Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
fungi. Following prior supportive care, patients may be 
refractory  to  additional  transfusion  support,  and 
therefore,  not  good  candidates  for  intensive 
myelosuppressive  chemotherapy.  Finally,  the  high 
frequency  of  unfavorable  cytogenetic  aberrations 
arising  during  or  after  chemoradiotherapy  appears  to 
result  in  the  rapid  emergence  of  chemotherapy 
resistance in t-AML  stem cells.  Relapses even after 
myeloablative chemoradiotherapy and allogeneic HCT 
are not uncommon. 
 
Outcomes  of  t-MN  Patients  with  “Good  Risk” 
Cytogenetics: It is now well recognized that APL and 
other  subtypes  of  AML  with  balanced  translocations 
sometimes occur as therapy-related myeloid neoplasms 
(t-MN)  in  patients  who  have  previously  received 
cytotoxic  therapy  or  ionizing  radiation  therapy 
(RT).
1,3,9  The  exact  mechanism  of  the  leukemogenic 
transformation  remains  to  be  determined.  The 
remainder  of  this  review  will  focus  on  “good  risk” 
leukemias, i.e. those with APL or inv(16)/t(16;16) or 
t(8;21). 
Among  511  patients  analyzed  at  the  International 
Workshop  on  the  Relationship  of  Prior  Therapy  to 
Balanced  Chromosome  Aberrations  in  Therapy-
Related  Myelodysplastic  Syndromes  and  Acute 
Leukemia held in Chicago in 2000, chromosome 21q22 
rearrangements were seen in 79 (~15%), inv(16) in 48 
[9%;  2  patients  had  t(16;16)],  and  t(15;17)  in  41 
(8%).
10 It was  noted  that  30% of t(15;17) cases  and 
21% of inv(16) cases  had received only  RT  as their 
primary  treatment,  and  this  was  significantly  more 
frequent  than  in  the  chromosome  11q23  (5%)  and 
21q22 (7%) cases (p<0.001). The majority of patients 
in all subgroups had received alkylating agents.  The 
chromosome 11q23 and 21q22 subgroups actually had 
the  highest  exposures  to  alkylating  agents  (86%  and 
82%, respectively); this was significantly greater than 
for the inv(16) and t(15;17) subgroups (63% and 59%, 
respectively). None of the t-APL patients had received 
the dioxypiperazine derivative, bimolane, once used in 
a  Chinese  study  for  treatment  of  psoriasis,  and 
associated with t(15;17). 
The disease was overt t-AML in 38 of 48 patients 
(79%) with an inv(16) and in 38 of 41 patients (93%) 
with  a  t(15;17).
11  Cases  with  inv(16)  had  a  short 
latency period (median, 22 months) and a long median 
survival, with 45% surviving for 5 years.  The median  
latency  for  t(15;17)  was  29  months,  and  the  median 
survival  29  months.  The  primary  disease for inv(16) 
cases  was  breast  cancer  (n=15),  lymphoma(12),and 
other solid tumors (16). For the t(15;17) cases, it was 
breast  cancer  (18),lymphoma  (11),and  other  cancers 
(12).  Twenty-six patients with inv(16) (54%) and 17 
with  t(15;17)  (41%)  had  additional  cytogenetic 
abnormalities; these were unrelated to age or survival 
in both subgroups. Trisomy 8 was the most common 
additional abnormality in both; +21, +22 and +13 were 
common in the inv(16) subgroup, and –7/del(7q) and –
5/del(5q)  were  present  in  a  few  cases  in  both 
subgroups. 
 
Outcomes  of  Patients  with  t-MN  and  T(15;17)  or 
Inv(16):  Thirty-three  of  39  patients  (85%)  with  an 
inv(16)  obtained  a  complete  remission  (CR)  after 
intensive chemotherapy, but 12 of these subsequently 
relapsed.
10  Four  underwent  HCT  using  bone  marrow 
stem cells, and one underwent peripheral blood stem 
cell transplantation. All 5 of these patients remained in 
CR at the time of last follow-up. The 6 patients with 
inv(16) who did not respond to intensive chemotherapy 
were  significantly  older  (median  age,  62  years)  as 
compared  to  the  33  responding  patients  (median,  44 
years) (P=0.012). 
Twenty-four of 35 patients (68%) with a t(15;17) 
obtained  a  CR  after  intensive  chemotherapy,  and  6 
patients subsequently relapsed. Two additional patients 
achieved a CR, but follow up data were missing. Two 
patients received an allogeneic HCT, and one was in 
CR at last follow-up. In the t(15;17) subgroup, the 11 
non-responding patients were similar in age to the 24 
responding  patients  (medians,  48  and  50  years, 
respectively;  p=0.99).  Several  patients  with  t(15;17) 
were  treated  with  all-trans-retinoic  acid  (ATRA, 
tretinoin),  but information  on  the  use  of  ATRA  was 
recorded inconsistently in the Workshop database. 
The median survival time was 29 months in both 
cytogenetic  subgroups,  and  many  patients  became 
long-term  survivors.    There  were  no  significant 
differences  in  survival  among  intensively  treated 
patients  with  or  without  additional  chromosome 
abnormalities  (log-rank  test,  p=0.16  for  the  inv(16) 
subgroup, and p=0.30 for the t(15;17) subgroup). The 
overall survival of 39 inv(16) patients with follow up 
data who had previously received chemotherapy with 
or  without  RT  (n=33)  for  their  primary  disease  was 
significantly  better  compared  to  patients  who  had 
received RT only (n=6) (log-rank test, P=0.03).  The 
difference in survival between primary chemotherapy 
with or without RT and RT only was not statistically 
significant in the t(15;17) subgroup (P=0.45). 
In the inv(16) subgroup, patients less than 55 years 
old  had  improved  survival  when  compared  to  older 
patients.  The  median  survival  for  the  26  younger 
patients had not been reached, but was only 12 months 
for the 13 older patients (log-rank, p=0.006). A similar 
tendency,  although  not  statistically  significant,  was 
observed in the t(15;17) subgroup, with median  
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survival  times  of  29  and  20  months  in  the  younger 
(n=21) and older (n=15) cohorts (p=0.73), respectively. 
 
Treatment  of  Patients  with  t-MN  and  t(15;17)  or 
inv(16): In 2003, Beaumont and colleagues reported on 
106 patients diagnosed with t-APL during the previous 
20 years in 3 European countries; 80 were diagnosed 
within the previous 10 years.
12 Primary disorders were 
predominantly  breast  cancer  (n=60),  non-Hodgkin 
lymphoma  (15),  and  other  solid  tumors  (25).  Thirty 
patients  had  received  chemotherapy  alone,  27  had 
received  RT  alone,  and  49  had  received  both.  Prior 
chemotherapy included at least one alkylating agent in 
68 patients and at least one topoisomerase-II inhibitor 
in  61,  including  anthracyclines  (30),  mitoxantrone 
(28),and epipodophyllotoxins (19).Median latency was 
25 months (range, 4 to 276 months). Characteristics of 
t-APL were generally similar to those of de novo APL.  
Survival was 59% at 8 years. 
Several  additional  series  of  patients  with  t-APL 
have recently been published.  Jantunen and colleagues 
in Finland reported on 5 cases; all had received prior 
RT;  4  had  received  topoisomerase-II  inhibitors  with 
multiagent  chemotherapy.
13  All  achieved  CR  with 
ATRA plus chemotherapy. One died from metastatic 
breast cancer and one relapsed; 3 remain in continuous 
CR  after  a  median  of  28  months.  Dayyani  and  co-
investigators  at  the  MD  Anderson  Cancer  Center 
reported on 29 patients with t-APL; 33% had received 
only prior RT.
14 Their median age was about 54 years 
compared with 42 years for a cohort of de novo APL 
patients treated at the same institution (p<0.001).  
Otherwise,  clinical  features  and  outcomes  were 
similar.    The CR rate was 89% for the 19 with t-APL 
who received ATRA plus arsenic trioxide (ATO), and 
70% for 10 who received ATRA  plus chemotherapy 
(p=0.35).  At  last  follow  up,  15  patients  (52%)  were 
alive;  9  had  died  from  leukemia.  Malhotra  and 
colleagues in India treated 3 patients with t-APL with 
ATRA plus ATO for induction and consolidation.
15 All 
3 remain in molecular remission at 19-42 months. 
In contrast to other subtypes of t-MN, patients who 
develop t-APL with t(15;17) or those with inv(16) have 
treatment outcomes that are similar to AML that arises 
de novo with the same chromosomal rearrangements. 
The combination of ATRA plus arsenic trioxide is an 
effective treatment for t-APL and may be particularly 
useful  for  patients  who  have  diminished  cardiac 
function  from  prior  anthracycline  exposure  or 
radiation.  Although  non-leukemia  co-morbidities  or 
persistent primary malignancy still impact on ultimate 
survival, their leukemia should be treated similar to de 
novo disease.
16   
 
Patients  with  t-MN  and  t(21q22):  The  Workshop 
identified 79 t-MN patients with balanced chromosome 
21q22  translocations;  44  (56%)  had  t(8;21),  11  as  a 
sole  abnormality  and  33  in  combination  with  other 
abnormalities.
17,18  Median  latency  was  39  months 
overall.  Patients  had  been  treated  for  solid  tumors 
(56%),  hematologic  malignancy  (43%),  and  juvenile 
rheumatoid  arthritis  (1  case)  with  RT  alone  (n=5), 
chemotherapy  alone  (36),  or  combined-modality 
therapy  (38).  All  5  who  had  received  only  RT  had 
t(8;21). Exposure to alkylating agents was significantly 
greater  than  for  the  inv(16)  and  t(15;17)  subgroups 
(p<0.02  for  both).  Exposure  to  topoisomerase-II 
inhibitors was significantly greater than in the t(15;17) 
subgroup  but  similar  to  inv(16).    Overt  t-AML  was 
present  at  diagnosis  in  82%  with  t(8;21).    Median 
survivals were 17 months for the 11 with only t(8;21) 
and  31  months  for  the  33  with  t(8;21)  plus  other 
abnormalities  (p=0.6).  Mutations  in  c-KIT  were  not 
studied in these patients.
19 Patients with t(8;21) had a 
more favorable outcome than those with other 21q22 
present  at  diagnosis  in  82%  with  t(8;21).    Median 
survivals were 17 months for the 11 with only t(8;21) 
and  31  months  for  the  33  with  t(8;21)  plus  other 
abnormalities  (p=0.6).  Mutations  in  c-KIT  were  not 
studied in these patients.
19 Patients with t(8;21) had a 
more favorable outcome than those with other 21q22 
rearrangements (p=0.014). Overall, median survival for 
the  21q22  patients  was  14  months,  and  for  patients 
with t(8;21) was 19 months. 
Recommendations  for  Treatment  of  t-MN: 
Figure  1  shows  a  treatment  algorithm  for  the 
management  of  patients  who  develop  therapy-related 
myeloid  neoplasms.    Primary  considerations  are  the 
patient’s  performance  status,  which  reflects  age,  co-
morbidities, the status of the primary disease, and the 
presence  of  complications  from  primary  therapy,  as 
well as the clonal abnormalities detected in the t-MN 
cells.    Mutations  in  c-KIT  were  not  studied  in these 
patients. 
In general, t-MN patients should be encouraged to 
participate  in  prospective  clinical  trials  that  are 
appropriately  designed  for  other  AML  patients  with 
similar cytogenetic abnormalities.  Patients who have 
an  HLA-matched  donor  should  be  considered  for 
allogeneic  HCT,  although  patients  with  favorable 
karyotypes such as t(15;17) and inv(16) may do well 
with conventional intensive chemotherapy.  
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